FORM PTO-1449 (REV: 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 2
ATTY: DOCKET NO. PAT033288-US-PCT

APPLICATION NO. 10/565455

APPLICANT Azria, Moise et al. FILING DATE July 22, 2004

Group 1646

			Ü.S. PA	TENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILI	NG DATE
	AA							
	AB							
	AC		•					
	AD							
	AE							
	AF							
	AG		i			-		
	AH							
	Al							
	ΑJ							
	AK							
	AL		4	· · · · · · · · · · · · · · · · · · ·				,
			FOREIGN	PATENT DOCUMENTS				
		DOCUMENT NUMBER DATE		ÖFFICE	CLASS	SUBCLASS	TRANSLATION YES NO.	
, · · · · · · · · · · · · · · · · · · ·	AM							
.73	AN	-						
	AO					,		
	AP				ļ	-		
	AQ							
		OTHER DOC	UMENTS (Inc	cluding Author, Title, Date, Pe	rtinent pages, E	tc.)		
÷								atism
	<u> </u>			dral Bone Remodeling in	Osteoarthritis	s", Arthritis &	Rheun	
	AR	Hayami et al., "The Ri Vol. 50, No. 4, pp. 119			Osteoarthritis	s", Arthritis &	Rheun	
		Vol. 50, No. 4, pp. 119 Tanko et al., "Safety a	93-1206, (2004 and Efficacy of	a Novel Salmon Calcitoni	n (sCT) Tech	nology-Base	d Oral	
	AR	Vol. 50, No. 4, pp. 119 Tanko et al., "Safety a Formulation in Health	93-1206, (2004 and Efficacy of y Postmenopa	a Novel Salmon Calcitoni usal Women: Acute and	n (sCT) Tech 3-month Effec	nology-Baseo	d Oral kers of	
	ÂŞ	Vol. 50, No. 4, pp. 119 Tanko et al., "Safety a Formulation in Health Trunover", Journal of Bingham et al., "Risec	93-1206, (2004) and Efficacy of y Postmenopa Bone and Mini Ironate Decrea	a Novel Salmon Calcitoni usal Women: Acute and eral Research, Vol. 19, No uses Biochemical Markers	n (sCT) Tech 3-month Effec 5. 9, pp. 1531 of Cartilage	nology-Baseots on Biomar -1538, (2004) Degradation	d Oral kers of out Do	f Bone
		Vol. 50, No. 4, pp. 119 Tanko et al., "Safety a Formulation in Health Trunover", Journal of Bingham et al., "Risec Decrease Symptoms	ond Efficacy of y Postmenopa Bone and Mini Ironate Decrea or Slow Radio	a Novel Salmon Calcitoni usal Women: Acute and oral Research, Vol. 19, No	n (sCT) Tech 3-month Effec 5. 9, pp. 1531 of Cartilage tlents With M	nology-Base its on Biomar -1538, (2004 Degradation edial Compar	d Oral kers of). out Doc tment	f Bone

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 2 ATTY, DOCKET NO. PAT033288-US-PCT

APPLICATION NO. 10/565455

APPLICANT Azria, Moise et al. FILING DATE July 22, 2004

Group 1646

U.S. PATENT DOCUMENTS EXAMINER INITIAL CLASS SUBCLASS **FILING DATE** NAME **DOCUMENT NUMBER** DATE BA BB BC BD BE BF BG BH BI BJ BK BL **FOREIGN PATENT DOCUMENTS** TRANSLATION YES NO SUBCLASS OFFICE CLASS DATE **DOCUMENT NUMBER** BM П BN П BO \Box BP BQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Buclin et al., "Bioavailability and Biological Efficacy of a New Oral Formulation of Salmon Calcitonin in Healthy Volunteers, Journal of Bone and Mineral Research, Vol. 17, No. 8, pp. 1478-1485, (2002). BR Manicourt et al., "Treatment with Calcitonin Suppresses the Responses of Bone, Cartilage, and Synovium in the Early Stages of Canine Experimental Osteoarthritis and Significantly Reduces the BS Seventy of the Cartilage Lesions", Arthritis & Rheumatism, Vol. 42, No. 6, pp. 1159-1167, (1999). BT DATE CONSIDERED EXAMINER 09/13/2009 /Xiaozhen Xie/

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.